ClinicalTrials.gg
CompletedNCT03901963AURIGAUpdated Jun 23, 2026Results posted

A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

A Phase 3 interventional study of Daratumumab and Lenalidomide in Multiple Myeloma, sponsored by Janssen Research & Development, LLC. Completed at 73 sites in 2 countries. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing daratumumab in Multiple Myeloma — 21 open to participants now, 63 under way, 10 of them phase 3. daratumumab · Multiple Myeloma.

Enrollment
30th of 132
200 · median 50
Started
2019
with 22 others
Phase 3
24 of 132
4 open now
Registered
61st of 132
by date
Lead sponsor
17 of 132
Janssen Research & Development, LLC

Among the 132 studies testing daratumumab in Multiple Myeloma, this one is the 30th largest by enrollment, is one of 23 that started in 2019, is one of 24 in phase 3, and was the 61st registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 132 studies testing daratumumab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About daratumumab

daratumumab: first FDA approval 2015 (DARZALEX), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing daratumumab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of differentiation 38 (CD38) treatment naive participants with newly diagnosed multiple myeloma who are MRD positive as determined by next generation sequencing (NGS) at screening, following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have newly diagnosed multiple myeloma with a history of a minimum of 4 cycles of induction therapy, have received high-dose therapy (HDT) and stem cell transplantation (ASCT) within 12 months of the start of induction therapy, and be within 6 months of ASCT on the date of randomization
  • Must have a very good partial response (VGPR) or better response assessed per International Myeloma Working Group (IMWG) 2016 criteria at the time of randomization
  • Must have archived bone marrow samples collected before induction treatment (that is, at diagnosis) or before transplant (for example, at the end of induction) or have existing results on the index multiple myeloma clone based on Adaptive Biotechnologies' next generation sequencing (NGS)-based minimal residual disease (MRD) assay. Archived bone marrow samples will be used for calibration of myeloma clonal cells to facilitate assessment of primary end point by NGS. If an existing result on index myeloma clone is available from Adaptive Biotechnologies' NGS-based MRD assay, as part of institutional procedures, an archived bone marrow sample is not required as long as Adaptive Biotechnologies is able to retrieve historical results on the index myeloma clone form the clinical database. Any one of the following archived samples are required: (a) Greater than 1 milliliter (mL) viable frozen bone marrow aspirated aliquot (preferred) collected in an ethylenediaminetetra-acetic acid (EDTA) tube, frozen, and stored at a temperature of -80 centigrade (°C), or; (b) Non-decalcified diagnostic bone marrow aspirate clot sections (block or slides) for MRD assessment: (i) A formalin fixed paraffin embedded (FFPE) block of bone marrow aspirate clot, or slides (preferably 5, if available), 5 micrometer each, of non-decalcified bone marrow, or; (ii) Slides (preferably 5, if available), bone marrow aspirate smear; (iii) Please note, bone marrow core sections are not acceptable samples for analysis; (iv) In exceptional circumstances when index myeloma clone cannot be identified from the archived bone marrow sample, a post-transplant sample can be used to identify myeloma clone with permission from the sponsor
  • Must have residual disease as defined by detectable MRD (Adaptive Biotechnologies' NGS based MRD assay)
  • Must have an (ECOG) performance status score of 0, 1, or 2

Exclusion criteria

Exclusion Criteria:

  • A history of (other than multiple myeloma) unless all treatment of that malignancy was completed at least 2 years before consent and the participant has no evidence of disease before the of date of randomization. Exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years
  • Must not have progressed on multiple myeloma (MM) therapy at any time prior to screening
  • Have had prior treatment/therapy with: (a) Daratumumab or any other anti-cluster of differentiation 38 (CD38) therapies, (b) Focal radiation therapy within 14 days prior to randomization with the exception of palliative radiotherapy for symptomatic management but not on measurable extramedullary plasmacytoma. Radiotherapy within 14 days prior to randomization on measurable extramedullary plasmacytoma is not permitted even in the setting of palliation for symptomatic management, or (c) Plasmapheresis within 28 days of randomization
  • Be exhibiting clinical signs of meningeal or central nervous system involvement due to multiple myeloma
  • Have known (COPD) with a (FEV1) less than (\<) 50 percent (%) of predicted normal
  • Have known moderate or severe persistent asthma within the past 2 years or current uncontrolled asthma of any classification
  • Have any of the following: (a) Known history of seropositivity for (HIV); (b) Seropositive for (defined by a positive test for hepatitis B surface antigen [HBsAg]. Participants with resolved infection (that is, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. EXCEPTION: Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR; (c) Seropositive for (anti-hepatitis C virus [HCV] antibody positive or HCV-RNA quantitation positive), except in the setting of a sustained virologic response, defined as aviremia at least 12 weeks after completion of antiviral therapy)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Daratumumab + Lenalidomide

    Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.

    Drug: Daratumumab · Drug: Lenalidomide

  • Active comparator
    Lenalidomide

    Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.

    Drug: Lenalidomide

Interventions

  • Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.

    Also known as: DARZALEX

  • Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)

    Percentage of participants who achieved MRD negative (MRD conversion) status from baseline to 12 months after maintenance treatment was defined as percentage of participants who were MRD positive at baseline (randomization) and achieved MRD negative status (at 10\^-5) during the time period from randomization to 12 months plus 2 months window, but prior to progressive disease (PD) and subsequent anti-myeloma therapy.

    Time frame: From randomization up to 12 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    Time frame: From randomization to either disease progression or death (up to 7.1 years)

  2. Percentage of Participants Who Achieved Overall MRD (at 10^-5) Negativity Conversion From Baseline to End of Study Treatment Period

    Time frame: From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)

  3. Percentage of Participants Who Achieved Durable (Greater Than or Equal to [>=] 12 Months) MRD Negative Status (10^-5)

    Time frame: From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)

  4. Response Rates by International Myeloma Working Group (IMWG) 2016 Criteria

    Time frame: From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)

  5. Overall Survival (OS)

    Time frame: From randomization up to 7.1 years

  6. Duration of Complete Response (CR)

    Time frame: From date of initial documentation of CR or sCR up to first documented disease progression or death due to disease progression whichever occurs first (up to 7.1 years)

  7. Health-related Quality of Life: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-C30 (EORTC QLQ-C30)

    Time frame: From baseline (Cycle 1 Day 1) up to 7.1 years

  8. Health-related Quality of Life: Change From Baseline in European Quality of Life Five Dimensions Questionnaire-5-level (EQ-5D-5L)

    Time frame: From baseline (Cycle 1 Day 1) up to 7.1 years

  9. Health-related Quality of Life: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Multiple Myeloma Module (EORTC QLQ-MY20)

    Time frame: From baseline (Cycle 1 Day 1) up to 7.1 years

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: From Cycle 1 Day 1 up to 30 days after the last study treatment or day prior to start of subsequent antimyeloma therapy (up to 7.1 years)

07

Results

Posted Apr 20, 2025

Participant flow

Participant flow — Overall Study
MilestoneDaratumumab + LenalidomideLenalidomide
Started99101
Treated9698
Completed510
Not completed9491
Withdrew: Lost to follow-up11
Withdrew: Physician decision12
Withdrew: Protocol violation11
Withdrew: Withdrawal by subject411
Withdrew: Ongoing8473
Withdrew: Randomized but not treated33

Outcome measures

PrimaryPercentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)

Percentage of participants who achieved MRD negative (MRD conversion) status from baseline to 12 months after maintenance treatment was defined as percentage of participants who were MRD positive at baseline (randomization) and achieved MRD negative status (at 10\^-5) during the time period from randomization to 12 months plus 2 months window, but prior to progressive disease (PD) and subsequent anti-myeloma therapy.

Time frame:
From randomization up to 12 months
Reported as:
Number · percentage of participants
Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)
percentage of participantsDaratumumab + LenalidomideLenalidomide
Percentage of Participants Who Had Minimal Residual Disease (MRD) Conversion From Baseline to 12 Months After Start of Maintenance Treatment as Determined by Next Generation Sequencing (NGS)50.5 (40.3 to 60.7)18.8 (11.7 to 27.8)
Statistical analysis
  • Daratumumab + Lenalidomide vs Lenalidomide · stratified Cochran-Mantel-Haenszel (CMH) · p = <0.0001 (Tested at 2-sided 0.05 significance level through stratified CMH method. Stratification factor included baseline cytogenetic risk per investigator') · Odds ratio (or): 4.51 · 95% CI 2.37 to 8.57Odds ratio and 95% CI were estimated by Mantel-Haenszel method. Stratification factor included baseline cytogenetic risk per investigator's assessment (high risk versus standard/unknown risk) as used for randomization of the study.
SecondaryProgression-free Survival (PFS)
Time frame:
From randomization to either disease progression or death (up to 7.1 years)

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved Overall MRD (at 10^-5) Negativity Conversion From Baseline to End of Study Treatment Period
Time frame:
From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieved Durable (Greater Than or Equal to [>=] 12 Months) MRD Negative Status (10^-5)
Time frame:
From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)

Results for this outcome have not been posted.

SecondaryResponse Rates by International Myeloma Working Group (IMWG) 2016 Criteria
Time frame:
From randomization up to 30 days after last dose of study treatment or disease progression or initiation of subsequent therapy, whichever occurs first (up to 3 years)

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)
Time frame:
From randomization up to 7.1 years

Results for this outcome have not been posted.

SecondaryDuration of Complete Response (CR)
Time frame:
From date of initial documentation of CR or sCR up to first documented disease progression or death due to disease progression whichever occurs first (up to 7.1 years)

Results for this outcome have not been posted.

SecondaryHealth-related Quality of Life: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-C30 (EORTC QLQ-C30)
Time frame:
From baseline (Cycle 1 Day 1) up to 7.1 years

Results for this outcome have not been posted.

SecondaryHealth-related Quality of Life: Change From Baseline in European Quality of Life Five Dimensions Questionnaire-5-level (EQ-5D-5L)
Time frame:
From baseline (Cycle 1 Day 1) up to 7.1 years

Results for this outcome have not been posted.

SecondaryHealth-related Quality of Life: Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Multiple Myeloma Module (EORTC QLQ-MY20)
Time frame:
From baseline (Cycle 1 Day 1) up to 7.1 years

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
From Cycle 1 Day 1 up to 30 days after the last study treatment or day prior to start of subsequent antimyeloma therapy (up to 7.1 years)

Results for this outcome have not been posted.

Adverse events

Collected over From Cycle 1 Day 1 up to 30 days after the last study treatment or day prior to start of subsequent antimyeloma therapy (up to 4.9 years). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daratumumab + Lenalidomide5/99 (5.1%)29/96 (30.2%)95/96 (99%)
Lenalidomide9/101 (8.9%)22/98 (22.4%)97/98 (99%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventDaratumumab + LenalidomideLenalidomide
PneumoniaInfections and infestations4/964/98
PyrexiaGeneral disorders3/960/98
AppendicitisInfections and infestations2/960/98
DiverticulitisInfections and infestations2/960/98
SepsisInfections and infestations2/961/98
Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/960/98
Cerebrovascular AccidentNervous system disorders2/960/98
Acute Kidney InjuryRenal and urinary disorders2/961/98
Covid-19 PneumoniaInfections and infestations1/962/98
HypercalcaemiaMetabolism and nutrition disorders0/962/98
Most frequent other events
Showing 10 of 245
Most frequent other events
EventDaratumumab + LenalidomideLenalidomide
NeutropeniaBlood and lymphatic system disorders62/9660/98
DiarrhoeaGastrointestinal disorders59/9654/98
FatigueGeneral disorders44/9646/98
Upper Respiratory Tract InfectionInfections and infestations40/9626/98
CoughRespiratory, thoracic and mediastinal disorders37/9636/98
HypokalaemiaMetabolism and nutrition disorders33/9636/98
ArthralgiaMusculoskeletal and connective tissue disorders32/9636/98
Back PainMusculoskeletal and connective tissue disorders31/9620/98
LeukopeniaBlood and lymphatic system disorders25/9628/98
Covid-19Infections and infestations27/9626/98

Baseline characteristics

Age, Continuous
Age, Continuous(years)Daratumumab + LenalidomideLenalidomideTotal
Mean61.3 ± 8.1260.8 ± 9.5461 ± 8.84
Sex: Female, Male
Sex: Female, Male(Participants)Daratumumab + LenalidomideLenalidomideTotal
Female384381
Male6158119
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Daratumumab + LenalidomideLenalidomideTotal
Hispanic or Latino9615
Not Hispanic or Latino8189170
Unknown or Not Reported9615
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Daratumumab + LenalidomideLenalidomideTotal
American Indian or Alaska Native011
Asian516
Black or African American202444
Native Hawaiian or Other Pacific Islander000
White6768135
More than one race112
Unknown or Not Reported224
Other448
Region of Enrollment
Region of Enrollment(Participants)Daratumumab + LenalidomideLenalidomideTotal
Canada202
United States97101198
08

Study locations

73 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35294, United States
  • Arizona Oncology Associates, PC - HAL
    Glendale, Arizona 85308, United States
  • Cancer Treatment Center of America Phoenix
    Goodyear, Arizona 85338, United States
  • University of California San Diego (UCSD) - The Rebecca and John Moores Cancer Center
    La Jolla, California 92093, United States
  • UCLA David Geffen School of Medicine
    Los Angeles, California 90095, United States
  • University of California San Francisco
    San Francisco, California 94143, United States
  • Colorado Blood Cancer Institute
    Denver, Colorado 80218, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • University of Colorado Health
    Fort Collins, Colorado 80528, United States
  • Yale University Medical Center
    New Haven, Connecticut 06510, United States
  • MedStar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
  • Cancer Specialists of North Florida
    Jacksonville, Florida 32256, United States
  • University of Miami Sylvester Cancer Center
    Miami, Florida 33136, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • University Cancer And Blood Center LLC
    Athens, Georgia 30607, United States
  • Illinois Cancer Specialists
    Niles, Illinois 60714, United States
  • Cancer Treatment Centers of America
    Zion, Illinois 60099, United States
  • Fort Wayne Medical Oncology and Hematology American Oncology Partners
    Fort Wayne, Indiana 46804, United States
  • Franciscan Health
    Indianapolis, Indiana 46237-8601, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66160, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40207, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion
    Detroit, Michigan 48202, United States
  • Cancer And Hematology Centers of Western Michigan PC
    Grand Rapids, Michigan 49503, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • HCA MidAmerica Division Inc Research Medical Center
    Kansas City, Missouri 64132, United States
  • Summit Medical Group/MD Anderson Cancer Center
    Florham Park, New Jersey 07932, United States
  • Rutgers, The State Univ of NJ-Robert Wood Johnson Medical School-The Cancer Institute of NJ (CINJ)
    New Brunswick, New Jersey 08901-1914, United States
  • New York Oncology Hematology
    Albany, New York 12206, United States
  • Northwell Health
    Lake Success, New York 11042, United States
  • NYU Winthrop
    Mineola, New York 11501, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Montefiore Einstein Center for Cancer Care
    The Bronx, New York 10467, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599-7305, United States
  • Levine Cancer Institute, Carolinas HealthCare System
    Charlotte, North Carolina 28204, United States
  • Novant Health Charlotte
    Charlotte, North Carolina 28204, United States
  • Novant Health
    Winston-Salem, North Carolina 27103, United States
  • Wake Forest Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45236, United States
  • Northwest Cancer Specialists PC
    Portland, Oregon 97227, United States
  • Oregon Health And Science University
    Portland, Oregon 97239, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107-4215, United States
  • Temple University Hospital Jeanes Campus
    Philadelphia, Pennsylvania 19111, United States
  • West Penn Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • University Of Pittsburgh Medical Center UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Reading Hospital/McGlinn Cancer Institute
    West Reading, Pennsylvania 19611, United States
  • Greenville Health System Cancer Institute
    Greenville, South Carolina 29615-4816, United States
  • Spartanburg Regional Health Services
    Spartanburg, South Carolina 29303, United States
  • Tennessee Oncology Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38120, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology-Central South
    Austin, Texas 78745, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75235, United States
  • Texas Oncology P A 1
    Dallas, Texas 75246, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Mays Cancer Center (UT Health San Antonio)
    San Antonio, Texas 78229, United States
  • Texas Oncology P A
    Tyler, Texas 75702, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • University of Virginia Cancer Center - Emily Couric Clinical Cancer Center - Women's Oncology Clinic
    Charlottesville, Virginia 22903, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • VA Puget Sound Healthcare System
    Seattle, Washington 98108, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • Cancer Care Northwest
    Spokane, Washington 99216, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5G 1X6, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • CHU de Quebec Universite Laval Hopital de l Enfant Jesus
    Québec, Quebec G1R 2J6, Canada
09

References and documents

Publications

  • Badros A, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin TS, Voorhees P. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025 Jan 16;145(3):300-310. doi: 10.1182/blood.2024025746. PubMed 39331724 ↗
  • Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21. PubMed 35985959 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Apr 2024, 59 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 59 months is above that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2019
First posted
Apr 3, 2019
StartActual
Apr 26, 2019
Primary completionActual
Apr 4, 2024
CompletionActual
May 4, 2026
Results first posted
Apr 20, 2025
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03901963
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
Apr 26, 2019
Primary completion
Apr 4, 2024
Completion
May 4, 2026
Results posted
Apr 20, 2025
Last update
Jun 23, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Daratumumab

Start the discussion